Nov 11, 2025 05:57AM Oppenheimer Reiterates Outperform Rating on Immunovant (IMVT)

Nov 10, 2025 07:32AM Immunovant, Inc. (IMVT) Misses Q2 EPS by 2c

Oct 14, 2025 06:06AM Truist Securities Starts Immunovant (IMVT) at Hold

Sep 4, 2025 06:24AM Oppenheimer Reiterates Outperform Rating on Immunovant (IMVT)

Sep 3, 2025 12:58PM Immunovant reports durability data for Graves' disease drug candidate

Aug 11, 2025 12:19PM Immunovant (imvt) PT Lowered to $57 at Citi

Aug 11, 2025 11:44AM Immunovant (IMVT) PT Lowered to $50 at Stifel

Aug 11, 2025 11:02AM Immunovant, Inc. (IMVT) Misses Q1 EPS by 1c

Jul 25, 2025 07:34AM Cantor Fitzgerald Reiterates Overweight Rating on Immunovant (IMVT)

Jul 10, 2025 06:29AM Goldman Sachs Resumes Immunovant (IMVT) at Neutral

May 30, 2025 06:41AM Immunovant (IMVT) PT Lowered to $35 at H.C. Wainwright

Apr 21, 2025 07:02AM Immunovant (IMVT) Announces Leadership Changes

Mar 20, 2025 12:01PM Immunovant (IMVT) PT Raised to $61 at Stifel

Mar 20, 2025 06:39AM H.C. Wainwright Reiterates Buy Rating on Immunovant (IMVT)

Mar 20, 2025 06:35AM Oppenheimer Reiterates Outperform Rating on Immunovant (IMVT)

Mar 20, 2025 06:07AM Citi Reiterates Buy Rating on Immunovant (IMVT)

Mar 19, 2025 07:45AM Roivant Sciences (ROIV) Announces Positive Results for Batoclimab Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy Studies

Mar 3, 2025 04:14AM Jefferies Starts Immunovant (IMVT) at Hold

Feb 25, 2025 06:59AM Piper Sandler: 'This Is the Right Time to Own Immunovant (IMVT) and Here Is Why'

Feb 10, 2025 07:28AM Immunovant (IMVT) PT Lowered to $44 at Guggenheim

Feb 10, 2025 06:40AM H.C. Wainwright Reiterates Buy Rating on Immunovant (IMVT)

Jan 23, 2025 05:01AM Immunovant (IMVT) PT Raised to $46 at Guggenheim

Jan 13, 2025 08:01AM Immunovant (IMVT) Announces $450 Million Private Placement

Jan 3, 2025 08:23AM Piper Sandler Explores Direct and Indirect Catalysts for Selected Biotechnology Companies

Dec 30, 2024 05:23PM Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

Oct 10, 2024 08:21AM Raymond James Resumes Immunovant (IMVT) at Outperform

Oct 9, 2024 06:10AM Immunovant (IMVT) PT Raised to $53 at Oppenheimer

Sep 30, 2024 07:25AM H.C. Wainwright Reiterates Buy Rating on Immunovant (IMVT)

Sep 25, 2024 08:22AM Goldman Sachs Reiterates Buy Rating on Immunovant (IMVT)

Sep 12, 2024 07:46AM Piper Sandler Reiterates Overweight Rating on Immunovant (IMVT)

Sep 10, 2024 06:40AM H.C. Wainwright Reiterates Buy Rating on Immunovant (IMVT)

Sep 9, 2024 02:33PM Immunovant (IMVT) PT Raised to Street High $60 at Citi, Remains Top Pick

Sep 9, 2024 01:22PM BofA Securities Reiterates Buy Rating on Immunovant (IMVT), PT $49, 'catalyst-rich 1H25'

Sep 9, 2024 11:56AM Goldman Sachs on Immunovant (IMVT): 'We view these data as compelling'

Sep 9, 2024 10:48AM Guggenheim on Immunovant (IMVT): 'we believe Graves' represents an underappreciated blockbuster commercial opp'y'

Sep 9, 2024 10:19AM Stifel on Immunovant (IMVT): 'upcoming data for Batoclimab in MG/CIDP (1Q25) remain important catalysts for the stock'

Sep 9, 2024 10:18AM Oppenheimer on Immunovant (IMVT): 'we see an attractive opportunity'

Sep 9, 2024 07:02AM Roivant Sciences (ROIV) Provides Update on Graves’ Disease Development Program

Sep 7, 2024 08:00PM Here's the list of biotech stocks that have key data catalysts in 2025

Aug 19, 2024 08:45AM Piper Sandler Reiterates Overweight Rating on Immunovant (IMVT)

Jul 30, 2024 07:17AM RBC's biotech survey shows investors more bearish vs. last time

Mar 17, 2024 08:00PM Top pharma stocks to own in 2024 – Citi